Sunshine Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
SBFM$2.85+3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
ITEM 15 EXHIBITS
| 1.1 | Underwriting Agreement, dated February 13, 2024 (1) |
| 3.1 | Articles of Incorporation (3) |
| 3.2 | Certificate of Amendment to Articles of Incorporation filed November 2, 2009 (5) |
| 3.3 | Statement of Share and Equity Capital Exchange (5) |
| 3.4 | Articles of Amendment to Articles of Incorporation filed July 13, 2010 (5) |
| 3.5 | Articles of Amendment to Articles of Incorporation filed May 27, 2015 (6) |
| 3.6 | Articles of Amendment to Articles of Incorporation (7) |
| 3.7 | Articles of Amendment to Articles of Incorporation (8) |
| 3.8 | Bylaws (15) |
| 4.1 | Description of Registrant’s Securities (17) |
| 10.1 | Patent Purchase Agreement with Advanomics Corporation (9) |
| 10.2 | Second Patent Purchase Agreement with Advanomics Corporation (10) |
| 10.3 | Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note (11) |
| 10.4 | Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note (11) |
| 10.5 | Form of Warrant, dated February 17, 2022 (2) |
| 10.6 | Warrant Agent Agreement between the Company and Equiniti, dated February 17, 2022 (2) |
| 10.7 | Sponsored Research Agreement, dated October 6, 2020, between the Company and the University of Georgia Research Foundation, Inc. (12) * |
| 10.8 | Research Agreement between the Company and Arizona Board of Regents on behalf of the University of Arizona (13) |
| 10.9 | Form of Warrant, dated March 14, 2022 (16) |
| 10.10 | Form of Amendment to Warrant, dated March 24, 2022 (18) |
| 10.11 | Employment Agreement between Sunshine Biopharma, Inc. and Dr. Steve Slilaty (19) |
| 10.12 | Form of Warrant, dated April 28, 2022 (20) |
| 10.13 | Share Purchase Agreement between Sunshine Biopharma, Inc., Malek Chamoun and Nora Pharma Inc. (21) |
| 10.14 | Employment Agreement between Sunshine Biopharma, Inc., Nora Pharma Inc. and Malek Chamoun (21) |
| 10.15 | License Agreement between the Company and the University of Arizona (22) * |
| 10.16 | Form of Warrant, dated May 16, 2023 (23) |
| 10.17 | Amendment No. 1 to Warrant Agent Agreement, dated October 18, 2023 (24) |
| 10.18 | 2023 Equity Incentive Plan (25) |
| 10.19 | Form of Warrant Agency Agreement (26) |
| 10.20 | Form of Pre-Funded Warrant (26) |
| 10.21 | Form of Series A Warrant (1) |
| 10.22 | Form of Series B Warrant (1) |
| 14.1 | Code of Ethics (14) |
| 21.1 | Subsidiaries (filed herewith) |
| 23.1 | Consent of BF Borgers CPA PC (filed herewith) |
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act (filed herewith) |
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act (filed herewith) |
| 32.1 | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) |
| 97.1 | Clawback policy (filed herewith) |
| EX-101 | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
|---|---|
| EX-104 | Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101). |
| * | Portions of the exhibit have been omitted. |
| (1) | Incorporated by reference to 8-K filed with the SEC on February 15, 2024. |
| (2) | Incorporated by reference to 8-K filed with the SEC on February 17, 2022. |
| (3) | Incorporated by reference to SB-2 filed with the SEC on October 19, 2007. |
| (4) | Incorporated by reference to 8-K filed with the SEC on November 6, 2009. |
| (5) | Incorporated by reference to 10-Q filed with the SEC on August 4, 2010. |
| (6) | Incorporated by reference to 8-K filed with the SEC on June 1, 2015. |
| (7) | Incorporated by reference to 8-K filed with the SEC on June 24, 2020. |
| (8) | Incorporated by reference to 8-K filed February 9, 2022. |
| (9) | Incorporated by reference to 8-K filed with the SEC on October 9, 2015. |
| (10) | Incorporated by reference to 8-K filed with the SEC on December 28, 2015. |
| (11) | Incorporated by reference to 8-K filed with the SEC on March 14, 2016. |
| (12) | Incorporated by reference to S-1/A filed with the SEC on January 24, 2022. |
| (13) | Incorporated by reference to 8-K filed with the SEC on February 25, 2022. |
| (14) | Incorporated by reference to 10-K filed with the SEC on May 1, 2020. |
| (15) | Incorporated by reference to 8-K filed with the SEC on April 19, 2023. |
| (16) | Incorporated by reference to 8-K filed with the SEC on March 15, 2022. |
| (17) | Incorporated by reference to 10-K filed with the SEC on March 21, 2022. |
| (18) | Incorporated by reference to 8-K filed with the SEC on March 24, 2022. |
| (19) | Incorporated by reference to 8-K filed with the SEC on April 8, 2022. |
| (20) | Incorporated by reference to 8-K filed with the SEC on April 28, 2022. |
| (21) | Incorporated by reference to 8-K filed with the SEC on October 20, 2022. |
| (22) | Incorporated by reference to 8-K filed with the SEC on February 28, 2023. |
| (23) | Incorporated by reference to 8-K filed with the SEC on May 16, 2023. |
| (24) | Incorporated by reference to 8-K filed with the SEC on October 20, 2023. |
| (25) | Incorporated by reference to S-8 filed with the SEC on January 8, 2024. |
| (26) | Incorporated by reference to S-1/A filed with the SEC on February 9, 2024. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.